Optimizing endurance exercise intensity prescription is crucial to maximize the clinical benefits and minimize complications for individuals at risk for or with cardiovascular disease (CVD). However, ...
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or ...
1 University Sheffield, Division of Clinical Medicine, Sheffield, United Kingdom 2 Weston Park Cancer Centre, Sheffield Teaching Hospitals National Health Service (NHS) Foundation Trust, Sheffield, ...
Copyright: © 2024 The Authors. Published by Elsevier Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results